PURPOSE: KRAS mutations confer adverse prognosis to CRC and no targeted therapies have shown efficacy in this patient subset. Paracrine, nongenetic events induced by KRAS mutant tumor cells are expected to result in specific deregulation and/or relocation of tumor microenvironment (TME) proteins, which in principle can be exploited as alternative therapeutic targets. EXPERIMENTAL DESIGN: A multimodal strategy combining ex-vivo/in vitro phage display screens with deep-sequencing and bioinformatics was applied to uncover TME-specific targets in KRAS mutant hepatic metastasis from CRC. Expression and localization of BCAM and LAMA5 were validated by immunohistochemistry in preclinical models of human hepatic metastasis and in a panel of human specimens (n=71). The anti-metastatic efficacy of two BCAM-mimic peptides was evaluated in mouse models. The role of BCAM in the interaction of KRAS mutant CRC cells with TME cells was investigated by adhesion assays. RESULTS: BCAM and LAMA5 were identified as molecular targets within both tumor cells and TME of KRAS mutant hepatic metastasis from CRC, where they were specifically overexpressed. Two BCAM-mimic peptides inhibited KRAS mutant hepatic metastasis in preclinical models. Genetic suppression and biochemical inhibition of either BCAM or LAMA5 impaired adhesion of KRAS mutant CRC cells specifically to endothelial cells while adhesion to pericytes and hepatocytes was unaffected. CONCLUSIONS: These data show that the BCAM/LAMA5 system plays a functional role in the metastatic spreading of KRAS mutant CRC by mediating tumor-TME interactions, and as such represents a valuable therapeutic candidate for this large, currently untreatable patient group.

BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS Mutant Colorectal Cancer

Bartolini A;Lamba S;Oddo D;Marchiò C;Cassoni P;Testori A;Bussolino F;Corà D;Di Nicolantonio F
Co-last
;
Marchiò S.
Co-last
;
2016

Abstract

PURPOSE: KRAS mutations confer adverse prognosis to CRC and no targeted therapies have shown efficacy in this patient subset. Paracrine, nongenetic events induced by KRAS mutant tumor cells are expected to result in specific deregulation and/or relocation of tumor microenvironment (TME) proteins, which in principle can be exploited as alternative therapeutic targets. EXPERIMENTAL DESIGN: A multimodal strategy combining ex-vivo/in vitro phage display screens with deep-sequencing and bioinformatics was applied to uncover TME-specific targets in KRAS mutant hepatic metastasis from CRC. Expression and localization of BCAM and LAMA5 were validated by immunohistochemistry in preclinical models of human hepatic metastasis and in a panel of human specimens (n=71). The anti-metastatic efficacy of two BCAM-mimic peptides was evaluated in mouse models. The role of BCAM in the interaction of KRAS mutant CRC cells with TME cells was investigated by adhesion assays. RESULTS: BCAM and LAMA5 were identified as molecular targets within both tumor cells and TME of KRAS mutant hepatic metastasis from CRC, where they were specifically overexpressed. Two BCAM-mimic peptides inhibited KRAS mutant hepatic metastasis in preclinical models. Genetic suppression and biochemical inhibition of either BCAM or LAMA5 impaired adhesion of KRAS mutant CRC cells specifically to endothelial cells while adhesion to pericytes and hepatocytes was unaffected. CONCLUSIONS: These data show that the BCAM/LAMA5 system plays a functional role in the metastatic spreading of KRAS mutant CRC by mediating tumor-TME interactions, and as such represents a valuable therapeutic candidate for this large, currently untreatable patient group.
22
19
4923
4933
http://clincancerres.aacrjournals.org/content/22/19/4923.long
colorectal cancer; KRAS; liver metastases; BCAM
Bartolini, A; Cardaci, S; Lamba, S; Oddo, D; Marchiò, C; Cassoni, P; Amoreo, Ca; Corti, G; Testori, A; Bussolino, F; Pasqualini, R; Arap, W; Corà, D; Di Nicolantonio, F*; Marchiò, S.; *co-last authors and corresponding authors
File in questo prodotto:
File Dimensione Formato  
clin cancer res_accesso aperto.pdf

Accesso aperto con embargo fino al 03/05/2017

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 11.53 MB
Formato Adobe PDF
11.53 MB Adobe PDF Visualizza/Apri
2016_Bartolini_ClinCanRes_Article&SI.pdf

Accesso riservato

Descrizione: Articolo principale (PDF Editoriale) e dati supplementari
Tipo di file: PDF EDITORIALE
Dimensione 2.13 MB
Formato Adobe PDF
2.13 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1562041
Citazioni
  • ???jsp.display-item.citation.pmc??? 25
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 34
social impact